SEP 08, 2020 9:04 PM PDT

Anticholinergic Drugs Reported to Cause Cognitive Decline

WRITTEN BY: Nouran Amin

A team of researchers have reported that a class of drugs used for an array of conditions—such as allergies, hypertension and urinary incontinence—could be associated with the increased likelihood of developing Alzheimer's disease (AD). These drugs are known as anticholinergic and they work by blocking acetylcholine activity.

"This study, led by Alexandra Weigand, suggests that reducing anticholinergic drug use before cognitive problems appear may be important for preventing future negative effects on memory and thinking skills, especially for people at greater risk for Alzheimer's disease," said senior author Lisa Delano-Wood, PhD, associate professor in the Department of Psychiatry at UC San Diego School of Medicine.

Findings were published in Neurology, the medical journal of the American Academy of Neurology.

Learn more about anticholinergic drugs:

"We believe this interaction between anticholinergic drugs and Alzheimer's risk biomarkers acts in a 'double hit' manner," said Weigand, the study's first author. "In the first hit, Alzheimer's biomarkers indicate that pathology has started to accumulate in and degenerate a small region called the basal forebrain that produces the chemical acetylcholine, which promotes thinking and memory. In the second hit, anticholinergic drugs further deplete the brain's store of acetylcholine. This combined effect most significantly impacts a person's thinking and memory."

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 24, 2020
Drug Discovery & Development
FDA Grants Emergency Approval for Blood Plasma to Treat COVID-19
AUG 24, 2020
FDA Grants Emergency Approval for Blood Plasma to Treat COVID-19
The US Food and Drug Agency (FDA) has given emergency approval for expanded use of antibody-rich blood plasma to help th ...
AUG 22, 2020
Drug Discovery & Development
New Class of Antibiotics Could Treat UTIs
AUG 22, 2020
New Class of Antibiotics Could Treat UTIs
At 11 million cases annually, urinary tract infections (UTIs) are the most common outpatient infections in the U.S., Sci ...
AUG 31, 2020
Cancer
Targeting Your Inner Hedgehog to Fight Chemoresistance in Colorectal Cancer
AUG 31, 2020
Targeting Your Inner Hedgehog to Fight Chemoresistance in Colorectal Cancer
Chemoresistance is a serious problem for many cancer therapies. Solutions to this problem are harder to come by than the ...
SEP 22, 2020
Drug Discovery & Development
New Treatment for Mouth-Hand-Foot Disease
SEP 22, 2020
New Treatment for Mouth-Hand-Foot Disease
A study appearing next week in the journal Nature Communications offers some good news in the search for antiviral drugs ...
OCT 12, 2020
Drug Discovery & Development
In vitro glycoengineering - Suitability for BioPharma manufacturing
OCT 12, 2020
In vitro glycoengineering - Suitability for BioPharma manufacturing
Introduction The importance of Fc glycosylation of monoclonal antibodies (mAbs) with regard to biological activity is wi ...
OCT 12, 2020
Cannabis Sciences
Can Cannabis Relieve Symptoms of Down Syndrome?
OCT 12, 2020
Can Cannabis Relieve Symptoms of Down Syndrome?
Increasing anecdotal and academic evidence has been emerging in recent years about the plethora of health benefits behin ...
Loading Comments...